JTX-4014

· Jounce Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JTX-4014, covering 2024-05-22 to 2024-05-22. Get the full timeline:

Most recent: Clinical Trial Update: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen [Phase 2]

See pricing